Oligonucleotide Synthesis Market worth $19.7 billion by 2029 | MarketsandMarkets Trademark

Oligonucleotide Synthesis Market Size by Product (Drugs (ASO, siRNA), Synthesized Oligo (Primer), Reagents, Equipment), Type (Custom, Predesigned), Application (Therapeutic (Neurology, Rare), Research (PCR, Sequencing), Diagnostics) - Global Forecast to 2029
The report "Oligonucleotide Synthesis Market by Product (Drugs (ASO, siRNA), Synthesized Oligo (Primer), Reagents, Equipment), Type (Custom, Predesigned), Application (Therapeutic (Neurology, Rare), Research (PCR, Sequencing), Diagnostics) - Global Forecast to 2029", is projected to reach USD 19.7 billion by 2029 from USD 8.8 billion in 2024, at a CAGR of 17.5% during the forecast period. One of the key factors driving the market growth is the growing acceptance of alternate therapies such as oligonucleotide based therapies for the treatment of neurological and rarae The incorporation of synthesized oligonucleotides to treat various diseases also supports market growth.

Browse 546 market data Tables and 67 Figures spread through 454 Pages and in-depth TOC on "Oligonucleotide Synthesis Market by Product (Drugs (ASO, siRNA), Synthesized Oligo (Primer), Reagents, Equipment), Type (Custom, Predesigned), Application (Therapeutic (Neurology, Rare), Research (PCR, Sequencing), Diagnostics) - Global Forecast to 2029"View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/oligonucleotide-synthesis-market-200829350.html

Probes accounted for the second-largest segment of the synthesized oligos product segment in 2023.

Probes are an important subsegment in the market for synthesized oligonucleotides. The segment accounted for the second-largest market share of the synthesized oligonucelotide market. This is due to high specificity and sensitivity of probes allowing their use in genetic research, pathogen detection, clinical diagnostics, and the study of gene expression patterns, offering insights into diverse biological processes and disease mechanisms. Techniques such as fluorescence in situ hybridization (FISH) utilize these probes for the detection of various genetic abnormalities that the root cause of several birth defects, neurological conditions and cancers among others.

Hospitals accounted for the largest share of the end-user segment in the oligonucleotide synthesis market in 2023.

By end user, hospitals accounted for the largest share of the oligonucleotide synthesis market in 2023. Growth in this market is largely driven by the significant number of FDA-approvals for oligonucleotide-based drugs especially antisense oligonucleotide drugs for rare and neurological diseases, increasing awareness towards alternative therapies and growing health-care spending.Ongoing research to develop oligonucleotide-based drugs for more common diseases such as cardiovascular diseases, supported by availability of reimubursement policies in developed economies are aiding this segment's growth.

The PCR subsegment accounted for the largest share of the research applications segment in the oligonucleotide synthesis market in 2023.

In 2023, PCR accounted for the largest share of the research application subsegment of the oligonucleotide synthesis market. PCR technologies such as real-time PCR or quantitative PCR (qPCR) used for both qualitative and quantitative analysis in the fields of molecular diagnostics, medicine, microbiology, and forensic biology are driving end-user demand. These PCR applications utilize sequence-specific primers, thus boosting the market for oligos (which are used as probes and primers) in the PCR market.

North America to register the highest CAGR in the oligonucleotide synthesis market.

The North America region is expected to show the highest CAGR of the oligonucleotide synthesis market. The growing investments in research and development by major pharmaceutical & biotechnology companies, increasing application of oligonucleotides in pharmaceutical drug research, and growing public & private sector investments in genomics and related technologies are expected to aid market growth in the North America.

Some leading players operating in the oligonucleotide synthesis market are Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), LGC Limited (UK), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), Maravai Lifesciences holdings, Inc. (US), Azenta, Inc. (US), Twist Bioscience Corporation (US) and Genscript Biotech Corporation (US). Major players in the oligonucleotide therapeutics market are Biogen Inc. (US), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), Astrazeneca (UK), Astellas Pharma Inc. (Japan), Jazz Pharmaceuticals Plc (Ireland), Nippon Shinyaku, Co. Ltd. (Japan), Ionis Pharmaceuticals, Inc. (US) and Novartis AG (Switzerland).

Don't miss out on business opportunities in Oligonucleotide Synthesis Market. Speak to our analyst and gain crucial industry insights that will help your business grow. [https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=200829350]

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=oligonucleotide-synthesis-market-worth-197-billion-by-2029-marketsandmarkets]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/oligonucleotide-synthesis-market-200829350.html

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.